<DOC>
	<DOCNO>NCT01934244</DOCNO>
	<brief_summary>This post approval , observational study conduct evaluate safety NovaSure Endometrial Ablation System perform presence Essure micro-inserts .</brief_summary>
	<brief_title>Post Approval NovaSure Essure Labeling Study</brief_title>
	<detailed_description>A prospective , single arm , multi-center , post approval study design provide additional information safety perform NovaSure Impedence Controlled Endometrial Ablation System presence Essure Permanent Birth Control System , follow Essure Confirmation Test confirm bilateral tubal occlusion satisfactory location Essure micro-inserts . The study conduct 15 clinical site enroll 318 patient . Patients meet inclusion none exclusion criterion study explain invited participate . Enrolled subject baseline data collect time NovaSure procedure follow 1 month NovaSure procedure assess adverse event .</detailed_description>
	<mesh_term>Menorrhagia</mesh_term>
	<criteria>Subject 18 year age old premenopausal . Subject 's gynecological history support use NovaSure endometrial ablation treatment menorrhagia . Subject Essure Permanent Birth Control System procedure . The Essure Confirmation Test confirm bilateral tubal occlusion satisfactory placement Essure microinserts . A write report ECT radiologic film need provide physician perform ECT . If neither available , ECT must repeat prior enrollment . Subject able provide inform consent Subject know suspect endometrial carcinoma ( uterine cancer ) premalignant condition endometrium , unresolved ( atypical ) adenomatous hyperplasia . Subject abnormal/obstructive uterine cavity confirm hysteroscopy imaging study ( e.g . congenital malformation , large fibroid large polyp ) Subject anatomic condition ( e.g . history previous classical cesarean section transmural myomectomy ) pathologic condition ( e.g . long term medical therapy ) could lead weaken myometrium . Subject active genital urinary tract infection time procedure ( e.g. , cervicitis , vaginitis , endometritis , salpingitis , cystitis ) . Subject intrauterine device ( IUD ) currently place . Subject active pelvic inflammatory disease history recent pelvic infection . Subject undiagnosed vaginal bleeding . ECT unable adequately assess bilateral tubal occlusion proper microinsert placement . Subject uterine sound measurement great 10 cm . Subject uterine cavity length le 4 cm . Subject uterine cavity width le 2.5 cm , determine width dial disposable NovaSure device follow device deployment . Subject unable comply protocol available follow In opinion investigator , subject medical condition precludes safe participation study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>